Comments Leave a Comment

    1-15 of 176 1 2 3 4 ... 10 11 12 »
    1. Mentioned In 176 Articles

    2. Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.

      ...demonstrate that concurrent inhibition of MDM2 and ALK was able to overcome ceritinib resistance conferred by MYCN upregulation in vitro and in vivo. Together, combined inhibition of ALK and MDM2 may provide an effective...
      Read Full Article
      Mentions: ALK MYCN
    3. MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group

      ...es of adrenal primary tumors, bone metastasis, and catecholamine secretion. Despite being more likely to have MYCN-amplified tumors, these patients have superior outcomes compared with patients with MIBG avid disease....
      Read Full Article
      Mentions: COG Imaging MYCN
    4. MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma.

      ...obiological characteristics and prognostic impact of MYCN amplification in NB metastatic to BM were analyzed. MYCN amplification was found in 16% of patients with metastases, and the results were consistent with the prim...
      Read Full Article
      Mentions: MYCN Bone Marrow LDH
    5. PD-L1 is a therapeutic target of the Bromodomain inhibitor JQ1 and, combined with HLA class I, a promising prognostic biomarker in neuroblastoma.

      ...taset of 477 human primary neuroblastomas from GEO and ArrayExpress databases was explored for PD-L1, MYC and MYCN correlation. Multivariate Cox regression analysis demonstrated that the combination of PD-L1 and HLA clas...
      Read Full Article
      Mentions: MYCN PD-1
    6. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

      ...and melphalan or to carboplatin, etoposide, and melphalan by minimisation, balancing age at diagnosis, stage, MYCN amplification, and national cooperative clinical group between groups. The busulfan and melphalan regimen...
      Read Full Article
      Mentions: SIOPEN MYCN SIOP
    7. 1-15 of 176 1 2 3 4 ... 10 11 12 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes about MYCN

    1. Children with a MYCN-amplification event, which occurs in about 25 percent of cases, have the poorest prognosis.
      In Loss of a microRNA family, let-7, found key in neuroblastoma
    2. Once a tumor has disrupted let-7 genetically, it doesn't need to amplify MYCN because it doesn't need to sponge let-7.
      In Loss of a microRNA family, let-7, found key in neuroblastoma
    3. We showed that maintenance of high MYCN protein levels is a key issue for this MYCN driven cancer. Neuroblastoma cells often have over 100 copies of the MYCN gene - so they produce an enormous amount of MYCN protein.
      In A way to target the Achilles heel of neuroblastoma